Unicycive Therapeutics (UNCY) Competitors $4.20 -0.05 (-1.18%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$4.23 +0.03 (+0.62%) As of 08/22/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock UNCY vs. HRTX, MDWD, VTYX, NLTX, TRDA, OGI, IPHA, GNFT, CTMX, and EPRXShould you be buying Unicycive Therapeutics stock or one of its competitors? The main competitors of Unicycive Therapeutics include Heron Therapeutics (HRTX), MediWound (MDWD), Ventyx Biosciences (VTYX), Neoleukin Therapeutics (NLTX), Entrada Therapeutics (TRDA), Organigram Global (OGI), Innate Pharma (IPHA), GENFIT (GNFT), CytomX Therapeutics (CTMX), and Eupraxia Pharmaceuticals (EPRX). These companies are all part of the "pharmaceutical products" industry. Unicycive Therapeutics vs. Its Competitors Heron Therapeutics MediWound Ventyx Biosciences Neoleukin Therapeutics Entrada Therapeutics Organigram Global Innate Pharma GENFIT CytomX Therapeutics Eupraxia Pharmaceuticals Unicycive Therapeutics (NASDAQ:UNCY) and Heron Therapeutics (NASDAQ:HRTX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, risk, earnings, analyst recommendations, institutional ownership, valuation and media sentiment. Which has higher valuation & earnings, UNCY or HRTX? Heron Therapeutics has higher revenue and earnings than Unicycive Therapeutics. Heron Therapeutics is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioUnicycive Therapeutics$680K109.08-$36.73M-$4.12-1.02Heron Therapeutics$144.29M1.49-$13.58M-$0.02-70.00 Do institutionals and insiders believe in UNCY or HRTX? 40.4% of Unicycive Therapeutics shares are held by institutional investors. Comparatively, 80.0% of Heron Therapeutics shares are held by institutional investors. 10.7% of Unicycive Therapeutics shares are held by company insiders. Comparatively, 5.9% of Heron Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Is UNCY or HRTX more profitable? Unicycive Therapeutics has a net margin of 0.00% compared to Heron Therapeutics' net margin of -0.62%. Heron Therapeutics' return on equity of 0.00% beat Unicycive Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Unicycive TherapeuticsN/A -243.13% -119.46% Heron Therapeutics -0.62%N/A -0.40% Do analysts prefer UNCY or HRTX? Unicycive Therapeutics presently has a consensus price target of $60.00, indicating a potential upside of 1,328.57%. Heron Therapeutics has a consensus price target of $4.50, indicating a potential upside of 221.43%. Given Unicycive Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Unicycive Therapeutics is more favorable than Heron Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Unicycive Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33Heron Therapeutics 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Which has more risk & volatility, UNCY or HRTX? Unicycive Therapeutics has a beta of 1.88, suggesting that its share price is 88% more volatile than the S&P 500. Comparatively, Heron Therapeutics has a beta of 1.15, suggesting that its share price is 15% more volatile than the S&P 500. Does the media favor UNCY or HRTX? In the previous week, Unicycive Therapeutics had 27 more articles in the media than Heron Therapeutics. MarketBeat recorded 28 mentions for Unicycive Therapeutics and 1 mentions for Heron Therapeutics. Heron Therapeutics' average media sentiment score of 1.28 beat Unicycive Therapeutics' score of 0.28 indicating that Heron Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Unicycive Therapeutics 4 Very Positive mention(s) 4 Positive mention(s) 20 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Heron Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryUnicycive Therapeutics beats Heron Therapeutics on 9 of the 16 factors compared between the two stocks. Get Unicycive Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for UNCY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding UNCY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart UNCY vs. The Competition Export to ExcelMetricUnicycive TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$75.06M$2.57B$5.76B$9.58BDividend YieldN/A1.67%4.41%4.10%P/E Ratio-1.0222.6131.1026.04Price / Sales109.08554.16435.26103.29Price / CashN/A180.4637.7358.48Price / Book4.525.939.536.61Net Income-$36.73M$31.83M$3.26B$265.56M7 Day Performance-10.64%1.89%2.10%1.95%1 Month Performance-8.89%1.33%2.82%-0.37%1 Year Performance11.11%8.84%30.56%19.02% Unicycive Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)UNCYUnicycive Therapeutics2.642 of 5 stars$4.20-1.2%$60.00+1,328.6%+10.5%$75.06M$680K-1.029Trending NewsAnalyst DowngradeHRTXHeron Therapeutics4.2078 of 5 stars$1.28-3.0%$4.50+251.6%-25.1%$201.38M$144.29M-64.00300Positive NewsHigh Trading VolumeMDWDMediWound1.4524 of 5 stars$18.72+0.5%$32.25+72.3%-6.2%$201.35M$20.22M-8.9680Analyst DowngradeVTYXVentyx Biosciences2.4644 of 5 stars$2.64-6.0%$10.00+278.8%+39.1%$200.38MN/A-1.5730NLTXNeoleukin TherapeuticsN/A$21.22-1.1%N/A-44.9%$199.43MN/A-6.8290TRDAEntrada Therapeutics3.0966 of 5 stars$5.02-3.3%$25.67+411.3%-61.9%$197.41M$210.78M-2.82110OGIOrganigram Global0.3952 of 5 stars$1.64+13.5%N/A-17.5%$193.67M$117.47M16.40860High Trading VolumeIPHAInnate Pharma1.721 of 5 stars$2.06-1.9%$11.00+434.0%-0.4%$193.59M$21.77M0.00220Short Interest ↑Gap UpGNFTGENFIT2.186 of 5 stars$3.73-1.8%$13.00+248.5%-2.8%$190.01M$76.77M0.00120News CoverageAnalyst ForecastAnalyst RevisionHigh Trading VolumeCTMXCytomX Therapeutics4.1016 of 5 stars$2.31-1.7%$5.75+148.9%+78.2%$189.46M$138.10M4.13170EPRXEupraxia Pharmaceuticals1.9886 of 5 stars$5.32+1.1%$11.00+106.8%+103.1%$189.15MN/A-7.0029News CoverageAnalyst ForecastGap Up Related Companies and Tools Related Companies Heron Therapeutics Alternatives MediWound Alternatives Ventyx Biosciences Alternatives Neoleukin Therapeutics Alternatives Entrada Therapeutics Alternatives Organigram Global Alternatives Innate Pharma Alternatives GENFIT Alternatives CytomX Therapeutics Alternatives Eupraxia Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:UNCY) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredCritical AI announcement set to ignite AI 2.0I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Unicycive Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Unicycive Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access